Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 6/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15934909 | 0.78 | ALDH1A1 (0.37) | BRD4TDP1 | |
| SCHEMBL20614414 | 0.74 | ALDH1A1 (0.38) | CHRNB2CHRNA4BRD4KMT2A | |
| SCHEMBL21977750 | 0.71 | BRD4 (0.38) | BRD4 | |
| SCHEMBL12414157 | 0.70 | CHRNB2 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL18073640 | 0.68 | BRD4 (0.35) | BRD4KDM5AKDM5BKMT2ARXFP1 | |
| SCHEMBL14981455 | 0.68 | BRD9 (0.42) | CHRNB2CHRNA4BRD4TDP1KMT2A | |
| SCHEMBL22017084 | 0.67 | KMT2A (0.35) | KDM5BKMT2ARXFP1 | |
| SCHEMBL23152952 | 0.64 | KMT2A (0.33) | KMT2ARXFP1 | |
| SCHEMBL486467 | 0.63 | — | — | |
| SCHEMBL13178899 | 0.63 | CHRNB2 (0.37) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | CHRNB2 2850/4885CHRNA4 2497/4885BRD4 288/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | CHRNB2 2850/4885CHRNA4 2497/4885BRD4 288/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | CHRNB2 203/4885CHRNA4 83/4885BRD4 507/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | CHRNB2 2850/4885CHRNA4 2497/4885BRD4 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.